ライフサイエンスコーパス: fungal infection

1 ted outcome of CLR ligation in bacterial and fungal infection.

2 structures for in situ, real-time imaging of fungal infection.

3 nnial indoor allergens and asthma related to fungal infection.

4 egs) using a model of Histoplasma capsulatum fungal infection.

5 ell as change to rice innate immunity during fungal infection.

6 vitro and in vivo and promotes Tregs during fungal infection.

7 l-arabitol or creatinine, is indicative of a fungal infection.

8 . oryzae, at multiple time points during the fungal infection.

9 patients, often without documented invasive fungal infection.

10 hat are likely related to localized areas of fungal infection.

11 nt inflammasome responses to a DNA virus and fungal infection.

12 ediates the activation of Syk in response to fungal infection.

13 ficient mice had increased susceptibility to fungal infection.

14 e prophylaxis group developed a breakthrough fungal infection.

15 imaging for patients with suspected invasive fungal infection.

16 ved in the proteins expressed in response to fungal infection.

17 g conditions to identify possible markers of fungal infection.

18 e of all BAL fluid samples were negative for fungal infection.

19 ize cell proliferation occurs independent of fungal infection.

20 xity regulating the fly response to systemic fungal infection.

21 rmin inhibited the innate immune response to fungal infection.

22 the susceptibility of these mice to systemic fungal infection.

23 type in the kidney and are protective during fungal infection.

24 o treat patients afflicted with this chronic fungal infection.

25 litis and are highly susceptible to invasive fungal infection.

26 l infection (64% Gram-negative) and 20% with fungal infection.

27 f these genes and enhanced susceptibility to fungal infection.

28 prescriptions for endophthalmitis caused by fungal infection.

29 the host cuticle during the early stages of fungal infection.

30 SE genes also increased significantly during fungal infection.

31 y an unacceptably high risk of postoperative fungal infection.

32 ls to suppress plant immunity and facilitate fungal infection.

33 ways that lead to Th17 cell activation after fungal infection.

34 gatively regulate host immune responses to a fungal infection.

35 subcutaneous nodule may be also ascribed to fungal infection.

36 y promoting the rapid control of respiratory fungal infection.

37 y, drug-induced lupus, allergic reaction, or fungal infection.

38 having symptoms, had laboratory evidence of fungal infection.

39 ial for ergosterol biosynthesis, to restrict fungal infection.

40 on of the insect reproductive tissues during fungal infection.

41 in improving the prognosis for patients with fungal infection.

42 ssion in wood compared to bark tissues after fungal infection.

43 l, we investigated the link between ESCC and fungal infection.

44 bute to the de novo biosynthesis of JA after fungal infection.

45 000Gy promoted browning of the calyx end and fungal infection.

46 NK1 may be a therapeutic target for treating fungal infection.

47 s available to treat drug-resistant invasive fungal infections.

48 o prevent and mitigate serious bacterial and fungal infections.

49 ve drugs have a higher incidence of invasive fungal infections.

50 Colony expansion is an essential feature of fungal infections.

51 s in the diagnosis and treatment of invasive fungal infections.

52 loping desperately needed therapies to treat fungal infections.

53 urses were not consistent with true invasive fungal infections.

54 ole currently used in the treatment of human fungal infections.

55 d to treat humans afflicted with filamentous fungal infections.

56 ould serve as a portal of entry for invasive fungal infections.

57 data are lacking from patients with invasive fungal infections.

58 d host niches such as in the brain to combat fungal infections.

59 han those in in serum in noncryptococcal CNS fungal infections.

60 therapies for both autoimmune conditions and fungal infections.

61 ntial for host defence against bacterial and fungal infections.

62 on used for prophylaxis or to treat invasive fungal infections.

63 complicated by tuberculosis reactivation and fungal infections.

64 andida albicans is a major cause of invasive fungal infections.

65 d immunity, resulting in opportunistic viral/fungal infections.

66 lant recipients) display the highest risk of fungal infections.

67 test has value in the diagnosis of invasive fungal infections.

68 hat provide protection against bacterial and fungal infections.

69 sceptibility to severe bacterial, viral, and fungal infections.

70 t defense against extracellular bacteria and fungal infections.

71 ave recurrent life-threatening bacterial and fungal infections.

72 nity may render these patients vulnerable to fungal infections.

73 linical management of patients with invasive fungal infections.

74 sential to maintain adequate protection from fungal infections.

75 atients with opportunistic, life-threatening fungal infections.

76 is to prevent life-threatening bacterial and fungal infections.

77 e innate immune system to recognize systemic fungal infections.

78 r, and about a billion people have cutaneous fungal infections.

79 treatment of disseminated, life-threatening fungal infections.

80 for developing novel strategies for treating fungal infections.

81 s none), sepsis (2.94 [2.70-3.21]), invasive fungal infection (1.20 [1.02-1.42]), and pneumonia (1.13

82 s none), sepsis (4.61 [4.34-4.89]), invasive fungal infection (1.24 [1.11-1.39]), and pneumonia (1.73

83 nces were found for invasive and superficial fungal infections (1.31; 95% CI, .46-3.72), invasive fun

84 disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79% and ven

85 f lower bacterial (32% vs 46%; P < 0.05) and fungal infection (2% vs 11%; P < 0.05).

86 nfections (1.31; 95% CI, .46-3.72), invasive fungal infections (2.85; .68-11.91), P. jirovecii pneumo

87 lin therapy (22.7% vs. 25.1%; P < 0.01), and fungal infections (3.3% vs. 4.4%; P < 0.01).

88 3 or worse adverse events were bacterial or fungal infections (47 [20%] of 232 in the intravenous PE

89 Invasive fungal infections, accompanied by high rates of mortalit

90 Angioinvasive fungal infections (AFIs) are an important cause of morbi

91 n with Candida species, the primary cause of fungal infection after corneal transplantation.

92 gnificant difference in bacterial, viral, or fungal infections after transplant.

93 As a rapid response to fungal infection an overexpression of phosphatidic acids

94 cell fates in inflammatory contexts of acute fungal infection and chronic autoimmunity.

95 entral tolerance, are susceptible to chronic fungal infection and esophageal squamous cell carcinoma

96 cyte/macrophage NADPH oxidase in controlling fungal infection and in limiting acute lung inflammation

97 Autoreactive CD4 T cells permit fungal infection and incite tissue injury and inflammati

98 tLYK3 is strongly repressed by elicitors and fungal infection and is induced by the hormone abscisic

99 Direct microscopic examination showed fungal infection and results of mycological culture were

100 ether this pathway contributes to persistent fungal infection and to determine whether anti-PD-1 Ab t

101 Fungal infection and wasp parasitization induced express

102 Softening, fungal infection and weight loss increased during cold s

103 DCAR-1 as being required for the response to fungal infection and wounding.

104 Six patients (5%) developed invasive fungal infections and 5 patients (4%) had life-threateni

105 by recurrent life-threatening bacterial and fungal infections and aberrant inflammation.

106 alidated tool for the clinical management of fungal infections and for epidemiological studies.

107 d for patients at risk for mycobacterial and fungal infections and for infection with B. pseudomallei

108 ellular defense in response to bacterial and fungal infections and rely on granular proteins to kill

109 disseminated mycobacterial and mucocutaneous fungal infections and was ultimately cured by cord blood

110 ral tolerance, autoreactive T cells, chronic fungal infection, and ESCCs expressing specific human ES

111 diverse as solid tumors, drug resistance in fungal infection, and normal development.

112 asured survival and pathogen load after live fungal infection, and we characterized the aphid immune

113 a albicans is an important cause of systemic fungal infections, and rapid diagnostics for identifying

114 tream processes that are required to promote fungal infection are poorly understood.

115 Opportunistic fungal infections are a leading cause of death among imm

116 Fungal infections are a major challenge to human health

117 Invasive fungal infections are an important infection concern for

118 Fungal infections are an increasing clinical problem.

119 Systemic fungal infections are an increasingly prevalent health p

120 ical and personal care applications in which fungal infections are endemic.

121 Fungal infections are of major relevance due to the incr

122 Fungal infections are on the rise, with mortality above

123 Fungal infections are responsible for millions of human

124 were impacted by the multistate outbreak of fungal infections as a result of contaminated methylpred

125 Interestingly, age may also affect skin fungal infections as certain dermatophytoses (i.e., tine

126 f major clinical patterns of travel-acquired fungal infection, as well as the fungi involved, and ris

127 ased susceptibility to bacterial, viral, and fungal infections, as well as autoimmunity.

128 es in host defenses, combating bacterial and fungal infections, as well as the pathogenesis of autoim

129 es occupied by Elysia, apparently to prevent fungal infection associated with Elysia feeding.

130 tifungal agents recommended for treatment of fungal infections associated with injection of contamina

131 ber 2012, we initiated an investigation into fungal infections associated with injections of preserva

132 roles in host defense against bacterial and fungal infections at different epithelial sites, but its

133 ing C12 or C14 with azoles to treat invasive fungal infections at lower administration doses or with

134 r graft-versus-host disease may prevent some fungal infections but increase the risk for others.

135 ognostic aid of central nervous system (CNS) fungal infection, but its relationship to serum values h

136 previously implicated in protection against fungal infection, but their roles in antifungal immunity

137 eding depression related to stress caused by fungal infection, but which was not associated with dens

138 ential for the defense against bacterial and fungal infections, but also contributes to tissue damage

139 first line of defense against bacterial and fungal infections, but they are also important effectors

140 Although the fungal infection by O. novo-ulmi primarily takes places

141 0.14) but significantly decreased secondary fungal infections by 50% (risk ratio, 0.49; 95% CI, 0.35

142 human neutrophils to the protection against fungal infections by Aspergillus fumigatus is essential

143 Multicellular organisms fight bacterial and fungal infections by producing peptide-derived broad-spe

144 Fungal infection carried a higher risk of mortality than

145 ection breaks down, superficial and invasive fungal infections cause diseases that range from irritat

146 Fungal infections cause morbidity worldwide and are asso

147 Invasive fungal infections cause significant morbidity and mortal

148 Invasive fungal infections cause significant morbidity and mortal

149 yngeal candidiasis (OPC) is an opportunistic fungal infection caused by Candida albicans.

150 andidiasis (OPC; thrush) is an opportunistic fungal infection caused by the commensal microbe Candida

151 Chromoblastomycosis (CBM) is a chronic fungal infection caused mainly by the melanized fungi Fo

152 osensors are suitable for early diagnosis of fungal infections caused by Candida sp. yeasts.

153 Fungal infections caused by Candida spp. represent an em

154 cal findings from this outbreak suggest that fungal infections caused by epidural and paraspinal inje

155 It is estimated that fungal infections, caused most commonly by Candida albic

156 g is associated with lower rates of invasive fungal infections compared with placebo or no interventi

157 ic, and therapeutic interventions, resistant fungal infections continue to cause significant morbidit

158 Opportunistic fungal infections continue to take an unacceptably heavy

159 of patients at risk for developing invasive fungal infections continues to increase.

160 or Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC/MSG) definiti

161 or Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and Mycoses Study Gr

162 or Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institu

163 or Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institu

164 or Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Ins

165 or Research and Treatment of Cancer Invasive Fungal Infections Cooperative Group/Mycoses Study Group

166 Invasive fungal infections developed in 11.1% (2 of 18) of micafu

167 virus, varicella zoster virus, bacterial and fungal infections) did not significantly differ between

168 , high-dose fluconazole treatment for severe fungal infections during pregnancy causes a pattern of b

169 e host response regulating specific types of fungal infections (e.g., mucocutaneous versus systemic).

170 Recurrent bacterial and fungal infections, eczema, and increased serum IgE level

171 Eumycetoma, a chronic fungal infection endemic in India, Indonesia, and parts

172 Therefore, autoreactive T cells and chronic fungal infection, fostered by inflammation and epithelia

173 gin, compared with placebo, did not increase fungal infection-free survival at day 28.

174 an increase in the proportion of filamentary fungal infections from the pre-2007 data.

175 ll lung cancer (adenocarcinomas) from benign fungal infection (granulomas) on 120 non-contrast CT stu

176 The incidence of systemic fungal infections has decreased in people with HIV in hi

177 wing need for newer agents to treat systemic fungal infections has escalated due to increasing resist

178 antifungal therapy, initiated for suspected fungal infection, has not been shown to improve outcome.

179 Invasive fungal infections have a high rate of morbidity and mort

180 Over the past several years fungal infections have shown an increasing incidence in

181 17), which is important in controlling other fungal infections, have not been clearly defined.

182 the increasing incidence of postkeratoplasty fungal infection, however, the addition of amphotericin

183 Invasive fungal infection (IFI) following liver transplant is ass

184 Invasive fungal infection (IFI) is associated with high mortality

185 ts with predefined risk factors for invasive fungal infection (IFI), a prospective phase II noncompar

186 hether empirical micafungin reduces invasive fungal infection (IFI)-free survival at day 28.

187 Prompt diagnosis of invasive fungal infections (IFI) remains a challenge.

188 Invasive fungal infections (IFIs) are a major cause of HIV-relate

189 Combat trauma wounds with invasive fungal infections (IFIs) are often polymicrobial with fu

190 e outbreaks have drawn attention to invasive fungal infections (IFIs) as an increasingly important pu

191 Invasive fungal infections (IFIs) cause significant morbidity and

192 ments in diagnosis and treatment of invasive fungal infections (IFIs) that complicate cancer chemothe

193 r transplant recipients at risk for invasive fungal infections (IFIs), GM and BG were assessed in 199

194 icafungin decreased the rate of new invasive fungal infection in 4 of 128 patients (3%) in the micafu

195 d before definitive diagnosis of an invasive fungal infection in critically ill patients without neut

196 me cases, reducing the incidence of invasive fungal infection in critically ill patients.

197 hip between autoreactive T cells and chronic fungal infection in ESCC development remains unclear.

198 gillosis (IA) is a life-threatening systemic fungal infection in immunocompromised individuals that i

199 oduction and increased mortality in systemic fungal infection in mice.

200 on for the variable clinical presentation of fungal infection in patients suffering from different im

201 A role for viral or fungal infection in patients with CRS is less clear.

202 ves accumulated significantly at the site of fungal infection in the lower epidermis.

203 tive period or had a history of bacterial or fungal infection in the preceding 30 days.

204 However, their role in fungal infection in vivo remains elusive.

205 lbicans is the most common cause of invasive fungal infections in humans.

206 ermatophytes cause superficial and cutaneous fungal infections in immunocompetent hosts and invasive

207 immunity plays a key role in protection from fungal infections in mice and man.

208 or prophylaxis and for treatment of invasive fungal infections in OTRs.

209 ndiagnosed fatal cases of early disseminated fungal infections in our heart transplant program, a ret

210 to identify the cause of systemic, dimorphic fungal infections in patients presenting to Groote Schuu

211 iciencies responsible for the higher risk of fungal infections in patients with immunosuppressive dis

212 year incidence of infection, particularly of fungal infections, in patients having received a MSC co-

213 ty-one recipients (21.6%) developed invasive fungal infections, including 29 patients (8.8%) with IPA

214 tions has correlated with a rise in clinical fungal infections, including cryptococcosis.

215 epithelial cells from damage during mucosal fungal infections independent of NF-kappaB or MAPK signa

216 that are produced in the tree in response to fungal infection inhibit C. polonica growth and can ther

217 recurrent fungal disease, and resistance to fungal infection is a complex trait.

218 identification of the agents of subcutaneous fungal infection is essential to guide appropriate antif

219 Fungal infection is highly associated with ESCCs in non-

220 rice transcriptome and its variation during fungal infection is necessary to understand the complex

221 ministered prior to diagnosis of an invasive fungal infection is not associated with either higher or

222 utility of molecular diagnostics in invasive fungal infections is discussed.

223 The proportion of postkeratoplasty fungal infections is rising steadily.

224 dida invasion, an important step in limiting fungal infection, is significantly reduced in mBD1-defic

225 GM), a non-culture-based surrogate marker of fungal infection, is widely used in diagnosis.

226 can increase susceptibility or bacterial or fungal infection, leading to hearing loss.

227 has considerable promise in the treatment of fungal infections like cryptococcal meningitis and C. al

228 nationwide outbreak of Exserohilum rostratum fungal infections, manifested initially as meningitis an

229 Finally, we suggest that other fungal infections may also result from hitherto unknown

230 Neonate susceptibility to fungal infections may not be due to an inability of thei

231 EntV(68) is protective in three fungal infection models at nanomolar or lower concentrat

232 , all tissue-based neutrophilic responses to fungal infections necessitate contact with the extracell

233 All serious fungal infections need appropriate antifungal therapy fo

234 n may serve as a reservoir for the recurrent fungal infections observed in these patients.

235 Invasive aspergillosis and other fungal infections occur in immunocompromised individuals

236 Compared with dectin-1-sufficient mice, the fungal infection of dectin-1(-/-) mice was more severe a

237 Nosemosis is a fungal infection of honey bees caused by either Nosema a

238 Lethal systemic fungal infections of Candida species are increasingly co

239 Isolated invasive fungal infections of unclear cellular basis are associat

240 uppressed patients at high risk for invasive fungal infections often have prolonged or repeated expos

241 However, the effects of fungal infection on host thermal limits have not been ex

242 We tested for effects of fungal infection on host thermal tolerance in a model sy

243 ory hospitalization did not reduce bacterial/fungal infection or significantly reduce NRM but did inc

244 confidence interval [CI], 1.1-1.8), invasive fungal infection (OR, 1.3; 95% CI, 1.1-1.5), and donor a

245 ation (ECMO) was the strongest predictor for fungal infection (OR, 29.93; 95% CI, 1.51-592.57, P=0.03

246 d year crop yield in the context of take-all fungal infection presented the opportunity to examine so

247 natural epidemics and tracked edible algae, fungal infection prevalence, body size, fecundity and de

248 e mortality and may have decreased secondary fungal infection rates.

249 umigatus, and is a leading cause of invasive fungal infection-related mortality and morbidity in pati

250 istic fungal pathogen and a leading cause of fungal-infection-related fatalities, especially in immun

251 Bacterial and fungal infections remain a major clinical challenge.

252 Fungal infections remain a major determinant of survival

253 Fungal infections remain a threat due to the lack of bro

254 Invasive fungal infection remains a serious postoperative complic

255 al spores by air sampling for acquisition of fungal infections remains to be determined.

256 Systemic fungal infections represent an important public health c

257 Coccidioidomycosis, an endemic fungal infection seen throughout the southwestern United

258 the epidemiology and risk factors for common fungal infections seen in lung transplant recipients, ev

259 The kidney that serves as the major site of fungal infection showed an initial rise in Cu, followed

260 Fungal infection stimulates the canonical C-type lectin

261 Azoles are antifungal drugs used to treat fungal infections such as candidiasis in humans.

262 Key secondary end points included new proven fungal infections, survival at day 28 and day 90, organ

263 sequences of an immune response to pulmonary fungal infection that can ultimately affect disease.

264 Eumycetoma is a debilitating, chronic, fungal infection that is endemic in India, Indonesia, an

265 Cryptococcal meningoencephalitis is a fungal infection that predominantly affects immunocompro

266 tissue specimens may be necessary to exclude fungal infections that fail to grow in culture.

267 ld potentially have therapeutic uses against fungal infections that have an anti-inflammatory compone

268 iosynthesis were actively transcribed during fungal infection, there was a significant time-dependent

269 esence of neutrophils in acute bacterial and fungal infections, these findings will have implications

270 The contribution of fungal infections to the morbidity and mortality of HIV-

271 of patients with cryptococcosis or dimorphic fungal infections treated with ISAV.

272 orescences of maize under local and systemic fungal infection treatments, respectively.

273 Systemic fungal infections trigger marked immune-regulatory distu

274 Together, these studies demonstrate that fungal infection triggers marked fluctuations in host Cu

275 , selective deficiencies to mycobacterial or fungal infection (typically heterozygous STAT1 mutations

276 ida albicans, the most common cause of human fungal infections, undergoes a reversible morphological

277 obesity: HR = 5.19, 95% CI: 3.38, 7.95), and fungal infections (underweight: HR = 3.19, 95% CI: 1.53,

278 ults and the development of postkeratoplasty fungal infection using corresponding corneal tissue.

279 rategy to enhance immunity for opportunistic fungal infections using T-cell gene therapy.

280 tality of construction/renovation-associated fungal infection was approximately 50%.

281 Overall, fungal infection was confirmed in 57% (8/14) of eyes by

282 Fungal infection was detected in 176 (74%) and Acanthamo

283 of L-ficolin in BAL fluid from patients with fungal infection was significantly higher than that for

284 elucidate the role of Notch signaling during fungal infections, we infected mice expressing the pan-N

285 Fruit parameters in terms of firmness, fungal infection, weight loss, total phenol concentratio

286 r at least 1 month for probable or confirmed fungal infection were eligible to complete a survey rega

287 es previously associated with development of fungal infections were analyzed from patient's DNA by us

288 ction were required in 5 patients, confirmed fungal infections were documented in 6, and 9 patients d

289 Viral and fungal infections were infrequent.

290 d with lower rates of mortality and invasive fungal infections when administered before definitive di

291 demonstrating that CHI3L1 is induced during fungal infection, where it acts as an immunomodulator to

292 arding significant risk factors for invasive fungal infection, which has limited the development and

293 atively low, but growing, number of systemic fungal infections, which creates significant hurdles in

294 IVCM sensitivity was higher in patients with fungal infections who had positive culture or longer dur

295 is new triazole in the treatment of invasive fungal infections will be better defined.

296 nary mucormycosis (PM) is a life-threatening fungal infection with an increasing incidence among pati

297 redisposed to mucormycosis, an angioinvasive fungal infection with high mortality.

298 Candida albicans is a leading cause of fungal infections worldwide.

299 and Fusarium species are important causes of fungal infections worldwide.

300 Candida albicans is the leading cause of fungal infections; yet, complex genetic interaction anal